Abstract
Immunotherapy, led by immune checkpoint inhibitors, has reshaped the landscape of tumor treatment, achieving long-acting drug responses in some patients with advanced malignancies, but not all patients can benefit from immunotherapy. In addition to primary drug-resistant patients, we cannot ignore hyperprogressive patients whose disease is accelerated instead after the use of immune checkpoint inhibitors, which are rare but often have a very poor prognosis and are prone to disputes. The mechanism of hyperprogression is still unknown, but not unknown, and some genetic mutations and biomarkers have been shown to be associated with a higher risk of hyperprogression. Clinicians should stratify patients with reference to markers and risk mutations to screen effective patients and inform them of the corresponding risks of immune checkpoint inhibitor therapy to ensure that patients make a fully informed choice of immunotherapy. Comply with evidence-based medical guidelines, standardize the use of medication, and timely monitor and intervene in related adverse events and hyperprogression. Under Chinese law, violation of the principles of diagnosis and treatment is subject to liability, except for those caused by the patient himself, such as backline treatment and sympathetic drug administration.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call